35 listed sites: Belgium (3); Canada (6); China (4); Poland (4); United States (18) - 14 Apr `26LY4005130 antibody treatment for nonsegmental vitiligo

LY4005130 antibody treatment for nonsegmental vitiligo

Official title: A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Status: Recruiting now

Description:

Eli Lilly and Company plans to enroll about 66 participants. LY4005130 is an experimental antibody that neutralizes XCL1 and XCL2 signals linked to harmful CD8 T cells. It is designed to reduce the immune attack on melanocytes and encourage repigmentation. Possible risks include infusion reactions, headache, and infections; its full safety profile is not yet known. People ages 18 to 75 may qualify. The study is recruiting at 35 listed sites across 5 countries.

Start date: April 14, 2026

Completion date: September 01, 2027

Organizer: Eli Lilly and Company

Contact: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Tel.: 1-317-615-4559

Email: LillyTrials@Lilly.com

Link: https://clinicaltrials.gov/study/NCT07533019

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference LY4005130 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Can chemicals cause vitiligo?

    Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...

  • What are rules for military service entry with vitiligo?

    Military service · Patient guide How do military-service rules for vitiligo differ across countries? There is no global standard. Every country writes its own entry rules, and m...

  • Shall I try low-fat diet for my vitiligo?

    The link between dietary fat and autoimmune diseases like vitiligo is a compelling yet complex puzzle that continues to intrigue scientists. While the conversation is ongoing, o...